Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Many cancer survivors suffer from anxiety. Anxiety may involve feelings of restlessness, muscle tension, and worry. Anxiety has also been linked to poor sleep, depressed mood, and tiredness. Researchers are doing this study to see how music therapy and cognitive behavioral therapy may be able to reduce anxiety and these other symptoms. Both music therapy and cognitive behavioral therapy are routinely used to treat anxiety.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
In this study, researchers want to see if the drug HER3-DXd works well against advanced melanoma. HER3-DXd is called an antibody-drug conjugate (ADC). ADCs are made up of an antibody linked to a drug. The antibody binds to specific proteins on cancer cells. The linked drug enters these cells and kills them without harming other cells.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Researchers want to find the best dose of CB-011 to treat multiple myeloma. The people in this study have multiple myeloma that keeps growing even after treatment.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
The purpose of this study is to find the highest doses of ruxolitinib and duvelisib when given together in patients with T-cell or NK-cell lymphoma that has come back or continued to grow despite prior treatment. The Food and Drug Administration (FDA) has approved ruxolitinib as a treatment for myelofibrosis and polycythemia vera (other blood disorders). The FDA has approved duvelisib to treat follicular lymphoma, small lymphocytic lymphoma, and chronic lymphocytic leukemia. The use of these two drugs together in this study is considered investigational.
The purpose of this study is to find the highest dose of the investigational immunotherapy drug TJ033721 that can be given safely in people with advanced cancers of the pancreas, esophagus, stomach, or junction between the esophagus and stomach. TJ033721 is an antibody that binds to Claudin 18.2, a protein expressed on some cancers cells, and to 4-1BB, a protein found on immune cells. TJ033721 may strengthen the immune system's ability to fight cancer cells by activating a patient's own cells to destroy the tumor. It is given intravenously (by vein).
